Dual mTORC1/2 inhibitors are proposed to be more effective.22,234 is an ATP-competitive inhibitor, binding to the active site of mTOR with a Ki of 1.4 nM, while achieving high selectivity versus PI3Ks (Ki > 200 nM),24 although this selectivity profile has been put in doubt.25 This candidate is currently under investigation for an array of cancers, predominantly solid tumours. The gene discussed is MTOR; the disease is cancer.